CareDx (CDNA) outlines $753,440 planned stock sale via Goldman Sachs

Rhea-AI Filing Summary

CareDx, Inc. filed a notice relating to a proposed sale of its common stock through Goldman Sachs & Co. LLC. The filing indicates a planned sale of 16,000 shares, with an aggregate market value of $753,440, on or about 08/04/2026 on NASD.

The securities to be sold were acquired from the issuer as compensation in the form of Restricted Stock Units, including awards dated 06/14/2025 for 10,570 shares and 03/07/2025 for 5,430 shares. The issuer’s common shares outstanding are listed as 51,734,223.

Key Figures

Planned shares to be sold: 16,000 shares Aggregate market value of sale: $753,440 Shares outstanding: 51,734,223 shares +3 more

6 metrics

Planned shares to be sold 16,000 shares Common stock proposed for sale via Goldman Sachs & Co. LLC

Aggregate market value of sale $753,440 Value of 16,000 common shares contemplated for sale

Shares outstanding 51,734,223 shares Issuer’s common shares outstanding listed in the notice

RSU award shares (June 2025) 10,570 shares Restricted Stock Units acquired as compensation on 06/14/2025

RSU award shares (March 2025) 5,430 shares Restricted Stock Units acquired as compensation on 03/07/2025

Contemplated sale date 08/04/2026 Date associated with proposed common stock sale on NASD

Key Terms

Restricted Stock Units, compensation, shares outstanding

3 terms

Restricted Stock Units financial

"Acquired as compensation -- Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

compensation financial

"Acquired as compensation -- Restricted Stock Units"

shares outstanding financial

"Common ... 51734223 ... shares outstanding context"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 06:10 PM Accepted by SEC EDGAR 08/04/2026 - 06:09 PM Learn about SEC filing dates

FAQ

What stock sale is CareDx (CDNA) registering in this Form 144-related filing?

CareDx is registering a proposed sale of 16,000 shares of its common stock. The shares are to be sold through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $753,440 and trading venue listed as NASD.

What is the value of the CareDx (CDNA) shares covered by this planned sale?

The planned sale covers shares with an aggregate market value of $753,440. This value relates to the proposed sale of 16,000 common shares of CareDx, to be executed through Goldman Sachs & Co. LLC on or about 08/04/2026.

How many CareDx (CDNA) shares are outstanding according to this filing?

The filing lists 51,734,223 CareDx common shares as outstanding. This figure provides context for the size of the proposed 16,000-share sale, indicating the broader capital base against which this contemplated transaction would occur.

How were the CareDx (CDNA) shares to be sold originally acquired?

The shares were acquired as compensation in the form of Restricted Stock Units. The filing identifies awards dated 06/14/2025 for 10,570 shares and 03/07/2025 for 5,430 shares, all granted directly by the issuer.

Who is the broker for the proposed CareDx (CDNA) share sale and where will it trade?

The proposed sale will be executed through Goldman Sachs & Co. LLC. The filing specifies that the 16,000 common shares are expected to trade on NASD, with an aggregate market value of $753,440 as disclosed.

On what date is the CareDx (CDNA) stock sale contemplated in this notice?

The contemplated sale date is listed as 08/04/2026. On or about this date, up to 16,000 shares of CareDx common stock, with an indicated value of $753,440, may be sold through Goldman Sachs & Co. LLC.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	16000	753440	51734223	08/04/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/14/2025	Acquired as compensation -- Restricted Stock Units	Issuer			10570	06/14/2025	Compensation
Common	03/07/2025	Acquired as compensation -- Restricted Stock Units	Issuer			5430	03/07/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)